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ABSTRACT 
In October 2014, the US Drug Enforcement Agency (DEA) reclassified hydrocodone from Schedule III to 
Schedule II of the Controlled Substances Act, resulting in a prohibition on refills in the initial 
prescription. While this schedule change was associated with overall decreases in the rate of filled 
hydrocodone prescriptions and opioid dispensing, available studies conflict regarding its impact on acute 
opioid prescribing among surgical patients. Here, we present the rationale and design of a planned study 
to measure the effect of hydrocodone rescheduling using a difference-in-differences design that leverages 
anticipated variation in the relative impact of this policy on patients treated by surgeons that more or less 
frequently prescribed hydrocodone products versus other opioids prior to the schedule change. 
Additionally, we present findings from preliminary study conducted on a subset of our full planned 
sample to assess for potential differences in outcome trends over the 3 years prior to rescheduling among 
patients treated by surgeons who commonly prescribed hydrocodone versus those treated by surgeons 
who rarely prescribed hydrocodone.   
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INTRODUCTION 
In October 2014, the US Drug Enforcement Agency (DEA) reclassified hydrocodone, a commonly used 
opioid analgesic, from Schedule III to Schedule II of the Controlled Substances Act.1 As a result of this 
change, hydrocodone prescriptions written after October 2014 were newly subject to regulations that 
aligned with existing prescribing rules for most other opioids. Most notably, this included a prohibition on 
prescribing refills in the initial prescription. At a population level, the hydrocodone schedule change was 
associated with marked decreases in the rate of filled hydrocodone prescriptions2, 3 as well as decreases in 
overall rates of opioid dispensing.4 
 
Despite this, the impact of the 2014 rescheduling of hydrocodone on patterns of acute opioid prescribing 
among surgical patients remains unclear. One report observed initial postoperative opioid prescriptions to 
contain greater quantities of opioids after versus before rescheduling, potentially indicating a negative 
unintended consequence of hydrocodone rescheduling by which restrictions on opioid refills encouraged 
larger initial prescriptions.5 A subsequent analysis failed to replicate these findings.6 Moreover, as past 
analyses of postoperative opioid prescribing after versus before hydrocodone rescheduling have not 
controlled for secular prescribing trends, they may be limited in their ability to identify causal 
relationships between this policy change and prescribing outcomes. Finally, past work has not examined 
the impact of hydrocodone rescheduling on important outcomes that may be influenced by changes in 
acute opioid prescribing patterns, such as the rate of long-term opioid use following surgery. 
 
Understanding the impact of hydrocodone rescheduling on short- and long-term opioid prescribing after 
surgery has major relevance to US health policy. Preventing excess opioid prescribing for acute 
indications, such as pain treatment after surgery, is a major target for policy interventions,7 and mitigating 
the development of new long-term opioid use represents an important aspect of the rationale underlying 
such efforts. To the extent that the 2014 rescheduling of hydrocodone may have altered surgeons' 
prescribing behaviors in the acute setting through impacts on the initial surgical prescription or by 
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limiting access to additional opioids via refills, it provides a unique opportunity to examine potential 
effects of changes in acute opioid prescribing behaviors on long-term opioid use outcomes. 
 
Given these considerations, we propose to test the association of the DEA’s 2014 rescheduling of 
hydrocodone with persistent postoperative opioid use within a sample of commercially insured US adults 
undergoing common general or orthopedic surgical procedures. To account for secular trends in 
prescribing around the time of the schedule change, we will use a difference-in-differences approach that 
will compare prescribing outcomes before versus after the schedule change across groups of patients who 
are more or less likely to experience the direct effects of this change based on their surgeon’s prior 
tendency to prescribe hydrocodone compared to other opioids for postoperative pain management. We 
hypothesize that, among patients treated by surgeons who commonly prescribed hydrocodone prior to the 
schedule change compared to those treated by surgeons who rarely or never prescribed hydrocodone, 
rescheduling led to a decrease in the rate of new persistent opioid use between 90 and 180 days after 
surgery due to decreases in opioid exposure in the immediate postoperative period.  
 
This technical preprint describes the data, research design, and analytic plan for our planned study. 
Additionally, it presents results from a preliminary analysis that used data on a subset of patients to be 
included in the final planned study sample who underwent surgical procedures prior to publication of the 
rescheduling final rule in August 2014. The primary purpose of this preliminary analysis was to assess 
differences in outcome trends prior to hydrocodone rescheduling among groups of patients treated by 
surgeons who commonly versus rarely prescribed hydrocodone as a means of assessing for evidence of 
potential violations of a key assumption of our planned difference-in-differences analysis, namely the 
presence of parallel pre-implementation outcome trends.8, 9 
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METHODS 
Overview of planned study design 
To estimate the effect of hydrocodone rescheduling on opioid prescribing and patient outcomes, we plan 
to undertake a difference-in-difference analysis that will divide patients into “exposed” and “unexposed” 
groups based on the anticipated impact that rescheduling would have on their care. To carry this out, we 
plan to take advantage of two key attributes of clinician opioid prescribing for surgery and other acute 
conditions in the US, namely: (1) that selection and dosage of opioids prescribed for pain treatment after a 
given surgery varies markedly across providers,10, 11 and (2) prescribing habits of individual providers 
tend to be stable over time.12-14 Therefore, we posit that clinicians who rarely prescribed hydrocodone 
products after surgery would have been minimally impacted by hydrocodone rescheduling; in contrast, we 
hypothesize that rescheduling would have had a marked impact on practice among those clinicians who 
commonly prescribed hydrocodone after surgery. Our analysis will thus estimate the impact of 
hydrocodone rescheduling by comparing opioid prescribing patterns before and after hydrocodone 
rescheduling among patients cared for by clinicians who frequently prescribed hydrocodone prior to the 
schedule change (“exposed”) versus those treated by clinicians who rarely or never prescribed 
hydrocodone (“unexposed.”) We reason that anticipatory changes in prescribing behavior may have taken 
place between the publication of the final rule regarding hydrocodone rescheduling on August 22, 2014 
and the effective date of the rule on October 6, 2014;1 therefore, we will consider dates prior to the 
publication of the final rule to represent the “pre-implementation” period, and dates on or after the rule’s 
effective date to represent the “post-implementation” period (Figure 1). 
 
Data source 
We will use data from the Optum® de-identifed Clinformatics® Data Mart Database, a US health 
insurance database with >15 million enrollees annually.  The database is geographically diverse 
representing all US states.  Compared to the insured US population overall, Optum has a lower proportion 
of older adults and is less racially and ethnically diverse, with fewer individuals of black race and 
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Hispanic ethnicity, but has comparable annual salary and education level.  This study has been exempted 
from review by the institutional review board of the University of Pennsylvania.   
 
Characterizing physician prescribing patterns prior to hydrocodone rescheduling 
To characterize groups of clinicians that differ in terms of hydrocodone prescribing after surgery, we will 
identify all individual providers or group practices that submitted 5 or more claims between August 22, 
2011 through August 21, 2014 for provision of at least one of 10 common orthopedic or general surgical 
procedures with an associated opioid prescription filled by the patient within 7 days of the procedure. 
Eligible procedures were identified based on Current Procedural Terminology (CPT) codes in physician 
claims and included: laparoscopic cholecystectomy; open cholecystectomy; inguinal hernia repair; 
laparoscopic appendectomy; open appendectomy; breast excision; carpal tunnel release; knee arthroscopy 
with or without meniscectomy; total knee replacement; and total hip replacement (Table 1).  Relevant 
opioids included oral analgesic formulations of codeine, hydrocodone, hydromorphone, levorphanol, 
meperidine, morphine, oxycodone, oxymorphone, pentazocine, tramadol, fentanyl, and tapentadol. For 
each identified individual provider or group practice, we next calculated the proportion of all initial opioid 
prescriptions written within 7 days of any of our 10 study procedures that was for a hydrocodone-
containing product. For the purposes of our analysis, we will categorize providers for whom hydrocodone 
Figure 1: Overview of study design. All data reported in this preprint come from the pre-implementation period 
(8/22/2011-8/22/2014); subsequent work will expand the analysis to include post-implementation data (10/6/2014-
10/5/2015) to estimate the policy effect of hydrocodone rescheduling on opioid prescribing via a difference-in-
differences analysis. We consider the period between the final rule announcement date for hydrocodone 
rescheduling (8/22/2014) and the final rule effective date (10/6/2014) to be the policy implementation phase; 
patients treated during this window are not included in analyses of pre-implementation outcome trends or the 
overall effect of the policy change. 
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products constituted 75% or more of initial opioid prescriptions as “hydrocodone prescribers;” we 
categorized providers for whom hydrocodone products constituted 25% or fewer of such prescriptions as 
“hydrocodone non-prescribers.”  
  
Defining the study sample 
The full analytic sample will include all patients 18 years of age and older with a submitted claim in the 3 
years prior to the publication of the final rule regarding hydrocodone rescheduling (i.e. August 22, 2011 
through August 21, 2014) or the year after the effective date of the schedule change (October 6, 2014 
through October 5, 2015), based on the date of the procedure or hospital discharge, whichever came later.  
For patients with more than one eligible surgery during the window, we will use the first procedure; 
patients with claims for more than one eligible procedure on the same day were excluded from the 
sample. Next, we will exclude patients for whom the performing provider falls outside the two categories 
described above (i.e. hydrocodone prescribed in 25% or fewer or 75% or more of all postoperative 
Table 1: Procedures included in the study sample 
1. Carpal Tunnel Release 64721; 29848 
2. Laparoscopic Cholecystectomy 47562; 47563; 47564 
3. Open Cholecystectomy 47600; 47605; 47610 
4. Inguinal Hernia Repair 49505; 49507; 49520; 49521; 49525 
5. Knee Arthroscopy—Meniscectomy & other 29881; 29880; 29877; 29875; 29876; 29870 
6. Total Knee Replacement 27446;27447; 27486; 27487 
7. Total Hip Replacement 27130; 27132* 
8. Laparoscopic Appendectomy 44970 
9. Open appendectomy 44950; 44960 
10. Breast excision 19301, 19302, 19120 
*Excluding any patient with an  International Classification of Diseases 9th Revision, Clinical 
Modification diagnosis code indicating hip fracture (820.00-820.9) 
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prescriptions), such that all patients in the sample received treatment from either a hydrocodone 
prescriber or a hydrocodone non-prescriber. To permit a uniform window for assessment of pre-surgery 
comorbidities and postoperative prescribing outcomes, we will restrict the sample to patients who had (a) 
at least 90 days of continuous enrollment prior to the procedure or index admission date (whichever came 
first) and (b) at least 180 days of enrollment after the procedure or index discharge date (whichever came 
last). Since the hypothesized effect of hydrocodone rescheduling would be related to new restrictions on 
refills following initial prescriptions, we will further restrict the sample to patients who filled a 
prescription for an opioid within 7 days following the surgical procedure. Finally, to ensure that our 
outcome measures captured new long-term opioid use as opposed to the continuation of established 
chronic use, we will restrict our sample to those patients with no filled opioid prescriptions in the 90 days 
prior to surgery (i.e. “opioid-naïve” individuals).  
 
Outcome 
Our primary outcome will be the incidence of any opioid prescription between 90 and 180 days after 
surgery among previously opioid-naïve individuals.16,17, 18 To assess mechanisms underlying any observed 
changes in the 30-day MME findings above, we will examine as secondary outcomes (1) the total amount 
of opioid (in MME) in the first postoperative prescription within 7 days of surgery or discharge, as 
measured in morphine milligram equivalents (MME), which we calculate using standard tables;15 (2) the 
incidence of any opioid refill in the first 30 days after surgery; and (3) the total amount of opioid across 
all prescriptions within the first 30 days after surgery or discharge. 
 
Covariates 
Demographics were collected from insurance registration files. We defined baseline comorbidities using 
all ICD-9-CM inpatient and outpatient codes in the 180 days prior to surgery using standard crosswalks 
based on algorithms published by Elixhauser and colleagues.19, 20 We created indicator variables 
corresponding to each of our 10 focal study procedures, as well as a variable to indicate whether the 
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relevant provider type was an individual practitioner or a group practice. Finally, we assessed whether the 
index surgical procedure was performed on an ambulatory vs inpatient basis, and created a variable to 
characterize the length of hospital stay among individuals undergoing inpatient procedures. 
  
Planned Statistical Analysis 
For each patient in the sample, we defined (a) a “pre-post” variable that indicated whether their date of 
surgery or hospital discharge fell before the date of final rule publication (August 22, 2014) vs on or after 
the rescheduling effective date (October 6, 2014) and (b) an “exposed-unexposed” variable indicating 
whether their treating physician was classified as a hydrocodone prescriber vs a hydrocodone non-
prescriber based on relevant cases performed in the 3 years prior to hydrocodone rescheduling. 
 
Initial analyses will compare patients treated by hydrocodone prescribers vs hydrocodone non-prescribers 
(“exposed” vs “unexposed”) with respect to patient characteristics, type of surgical procedure, and prior 
opioid use using standardized mean differences for continuous variables and standardized differences in 
proportion for categorical variables. We will graphically explore changes in outcomes relative to the date 
of hydrocodone rescheduling by plotting each outcome by group in 3 month intervals in the 3 years prior 
to the schedule change and the year following the schedule change. 
 
We will fit regression models to predict each of the above-specified outcomes. For binary outcomes, we 
will use logistic regression; as we expected the distribution of MME values to be skewed, analyses of 
MME-based outcome variables will use generalized linear models with a gamma distribution. For a given 
outcome, each model predicts that outcome as a function of an interaction between the “pre-post” 
indicator and the “exposed-unexposed” indicator while controlling for all of the above covariates. We will 
consider an interaction term in this model that was significantly different from zero to indicate an effect 
of hydrocodone rescheduling on the relevant outcome, using P<0.05 as our threshold for determining 
statistical significance. The magnitude of the policy effect on each outcome will be assessed based on the 
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regression coefficient for the interaction between “pre-post” and “exposed-unexposed.” All models will 
use robust standard errors to account for clustering of observations within providers.21 Analyses are 
conducted with SAS software version 9.4 (SAS Institute, Cary, NC). 
 
Preliminary analyses:  testing for parallel pre-implementation trends 
A key assumption of difference-in-difference analyses is that trends in outcomes for exposed and 
unexposed groups are the same prior to the intervention or policy change under evaluation.8, 9 As a 
prerequisite to our main study, we undertook a preliminary analysis within a subset of our full planned 
study sample to assess for potential violations of this “parallel trends assumption” by examining the 
trends for all outcomes among patients treated by hydrocodone prescribers versus hydrocodone non-
prescribers over the 3 years prior to the publication of the final rule for hydrocodone rescheduling in 
August 2014. Of note, this period corresponds to the “pre-implementation” phase of the planned analysis 
described above. Subsequent work will examine the data presented here plus data on patients treated in 
the 12 months following the effective date of hydrocodone rescheduling (i.e. the “post-implementation” 
period) to estimate the policy impact of hydrocodone rescheduling on opioid prescribing patterns after 
surgery. 
  
Our preliminary analysis used inclusion and exclusion criteria and definitions for exposures, outcomes, 
and covariates as described above. Initial analyses used descriptive statistics to characterize patients 
treated by hydrocodone prescribers versus non-prescribers over the pre-implementation period. We 
examined trends in each of our outcomes among the exposed and unexposed prior to policy 
implementation via two methods. First we plotted and visually inspected trends for each of our 4 study 
outcomes over the 3 years prior to the hydrocodone rescheduling final rule publication date, by exposure 
group. Next, we regressed each outcome on the interaction of the binary exposure status variable (i.e. 
treatment by a hydrocodone prescriber vs. treatment by a hydrocodone non-prescriber) with indicators for 
each of the 3 years preceding the policy change among procedures performed prior to the final rule 
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publication date, controlling for all above covariates. Analyses of binary outcomes used logistic 
regression; analyses of MME-based outcome variables used generalized linear models with a gamma 
distribution. We considered a finding of statistical significance for the interaction of exposure group with 
time in the period prior to the exposure to suggest a potential violation of the parallel trends assumption 
based on differences in trends in outcomes across the exposure and control group. As is planned for our 
main analysis, all models used robust standard errors to account for clustering of observations within 
providers and were conducted SAS software version 9.4 (SAS Institute, Cary, NC). 
 
 
RESULTS 
 
Characterizing clinician prescribing patterns prior to hydrocodone rescheduling 
 
From August 22, 2011 through August 22, 2014, we identified 443,676 patients who received relevant 
procedures performed by 104,868 individual providers or group practices. Of these, 12,366 providers had 
at least 5 eligible procedures over the period with an associated opioid prescription within 7 days of the 
procedure date. Across all providers, the median proportion of hydrocodone out of postoperative opioid 
prescriptions was 60% (interquartile range 29%, 83%). There were 4,620 providers, including 3,659 
individual providers and 961 group practices who prescribed hydrocodone for at least 75% of all 
postoperative prescriptions and were classified as hydrocodone prescribers. 2,798 providers, including 
2,275 individual providers and 523 group practices prescribed hydrocodone for 25% or fewer of all 
postoperative prescriptions and were classified as hydrocodone non-prescribers. 
 
Defining the exposed and unexposed cohorts 
Following exclusions, we identified 52,127 patients who underwent a relevant procedure by a 
hydrocodone prescriber or a hydrocodone non-prescriber within the 3 years prior to the hydrocodone 
schedule change announcement. 33,319 (63.9%) of these cases were performed by hydrocodone 
12 
 
prescribers and 18,808 (36.1%) were performed by non-prescribers (Figure 2). Table 2 compares 
hydrocodone non-prescribers, those treated by hydrocodone prescribers were more often treated on an 
outpatient basis and more often underwent carpal tunnel release and knee arthroscopy procedures. Total 
Figure 2: Creation of the preliminary analysis sample 
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joint replacement procedures were more common among patients treated by hydrocodone non-
prescribers. Prior to hydrocodone rescheduling, the initial opioid prescription filled within 7 days after 
surgery was for a hydrocodone product in 89.8% of those treated by hydrocodone prescribers, versus 
11.5% of those treated by hydrocodone non-prescribers. 
Table 2. Characteristics of patients included in analyses of outcome trends prior to 
announcement of hydrocodone rescheduling in August 2014. 
Covariate 
Patients treated by surgeons 
prescribing hydrocodone in 
≤ 25% of eligible cases 
(N=18,808) 
Patients treated by surgeons 
prescribing hydrocodone in ≥ 
75% of cases 
(N=33,319) 
Age, Median (IQR) 54.0 (42.0-64.0) 52.0 (40.0-62.0) 
Sex, N (%)   
Male  8,700 (46.3) 15,221 (45.7) 
Female  10,102 (53.7) 18,094 (54.3) 
Provider type, N (%)   
Individual 12,894 (68.6) 21,508 (64.6) 
Group practice 5,914 (31.4) 11,811 (35.4) 
Length of stay, N (%)   
0 days 12,502 (66.5) 26,709 (80.2) 
1or 2 days 3,131 (16.6) 3,112 (9.3) 
3 or more days 3,175 (16.9) 3,498 (10.5) 
Procedure type, N (%) 
Laparoscopic cholecystectomy 4,308 (22.9) 8,433 (25.3) 
Open cholecystectomy 106 (0.6) 189 (0.6) 
Laparoscopic appendectomy 1,646 (8.8) 2,866 (8.6) 
Open appendectomy 175 (0.9) 234 (0.7) 
Inguinal hernia repair 2,360 (12.5) 3,772 (11.3) 
Carpal tunnel release 1,049 (5.6) 3,814 (11.4) 
Knee arthroscopy  3,114 (16.6) 7,420 (22.3) 
Total knee replacement 2,937 (15.6) 2,518 (7.6) 
Total hip replacement 1,615 (8.6) 1,094 (3.3) 
Breast excision 1,498 (8.0) 2,979 (8.9) 
Comorbidities, N(%) 
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Table 2. Characteristics of patients included in analyses of outcome trends prior to 
announcement of hydrocodone rescheduling in August 2014. 
Covariate 
Patients treated by surgeons 
prescribing hydrocodone in 
≤ 25% of eligible cases 
(N=18,808) 
Patients treated by surgeons 
prescribing hydrocodone in ≥ 
75% of cases 
(N=33,319) 
Congestive heart failure 400 (2.1) 592 (1.8) 
Cardiac arrhythmia 1,706 (9.1) 2,810 (8.4) 
Cardiac valve disease 862 (4.6) 1,165 (3.5) 
Peripheral vascular disorders 566 (3.0) 927 (2.8) 
Hypertension, uncomplicated 7,416 (39.4) 12,227 (36.7) 
Hypertension, complicated 601 (3.2) 883 (2.7) 
Other neurological disorders 306 (1.6) 498 (1.5) 
Chronic pulmonary disease 2,338 (12.4) 3,587 (10.8) 
Diabetes, uncomplicated 2,289 (12.2) 3,983 (12.0) 
Diabetes, complicated 455 (2.4) 844 (2.5) 
Hypothyroidism 2,367 (12.6) 3,932 (11.8) 
Renal Failure 499 (2.7) 790 (2.4) 
Liver disease 1,239 (6.6) 2,316 (7.0) 
Solid tumor without metastasis 1,545 (8.2) 2,642 (7.9) 
Rheumatoid arthritis 584 (3.1) 879 (2.6) 
Coagulopathy 320 (1.7) 411 (1.2) 
Obesity 2,781 (14.8) 4,191 (12.6) 
Fluid and electrolyte disorders 1,077 (5.7) 1,566 (4.7) 
Deficiency anemia 518 (2.8) 696 (2.1) 
Depression 2,089 (11.1) 3,309 (9.9) 
Antidepressant receipt in last 90 days 2,716 (14.4) 5,128 (15.4) 
 
Measuring the effect of hydrocodone rescheduling on the study outcomes 
Figure 3 depicts trends over time for each of the study outcomes prior to hydrocodone rescheduling; 
visual inspection of pre-implementation trends by group did not reveal marked differences in outcome 
rates over time. In adjusted models examining data from the pre-rescheduling period only, the interaction 
of the binary exposure status variable with the year variable was non-significant for receipt of any opioid 
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between 90 and 180 days after surgery (P=0.22); total MME received in the first 30 days after surgery 
(P=0.29); and receipt of any refill within 30 days (P=0.75). The interaction of the exposure status variable 
with the year indicator was significant for total MME received within 7 days of surgery (P=0.005). The 
coefficient for the interaction of exposure status with the 3rd (most recent) pre-announcement year versus 
the 1st (earliest) year was -10.9 MME (95% CI -19.6, -2.2, P=0.014). The coefficient for the interaction 
of exposure status with the 2nd (intermediate) pre-announcement year (vs year 1) was -13.9 MME (95% 
CI -22.7, -5.1, P=0.002). 
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C D
Figure 3: Pre-implementation trends by surgeon prescriber group for (A) any filled opioid prescription between 90 and 180 days; (B) 
total amount of opioid dispensed in MME at 7 days; (C) any refill within 30 days of surgery; (D) total amount of opioid dispensed in 
Morphine Milligram Equivalents (MME) d at 30 days. Blue lines indicate treatment by a surgeon prescribing hydrocodone in ≤ 25% of 
cases; red lines indicate treatment by a surgeon prescribing hydrocodone in ≥ 75% of cases.
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DISCUSSION 
 
We present the rationale and design of a planned study to assess the impact of the US FDA’s rescheduling 
of hydrocodone in 2014 from Category II to Category III of the controlled substances act on opioid 
prescribing practices after surgery. The proposed analysis will address key gaps in knowledge related to 
the impact of this policy on practice. It will employ difference-in-difference analysis, a strong inferential 
design, that will go beyond prior work by comparing patterns of postoperative opioid receipt before and 
after rescheduling among groups of patients likely to experience differential effects of hydrocodone 
rescheduling. Additionally, it will examine opioid prescribing outcomes beyond the immediate period 
after surgery to examine the downstream impact of hydrocodone rescheduling on the development of new 
long-term opioid use among previously opioid-naïve surgical patients. Finally, the proposed analysis will 
take advantage of a large and representative national claims dataset.  
 
Analyses presented here support the feasibility and rationale of our planned analytic approach. 
Specifically, using data from the three years prior to the publication of the final rule on hydrocodone 
rescheduling, we have demonstrated that distinct comparison groups of surgical patients can be 
constructed based on surgeons’ established prescribing patterns to preferentially prescribe or avoid 
hydrocodone products for postoperative pain control. Of note, we find low-risk procedures such as carpal 
tunnel release and knee arthroscopy constitute a greater proportion of all cases performed by hydrocodone 
prescribers as compared to hydrocodone non-prescribers. While it is likely that differences in prescribing 
patterns may relate to surgeons’ individual habits or practice styles this specific finding suggests that 
selection of hydrocodone versus other products may also relate to anticipated pain severity. From the 
standpoint of our planned analysis, this observation highlights the importance of adjustment for case mix 
differences between exposure and control groups. 
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Additionally, our preliminary analysis does not find evidence for violations of the parallel trends 
assumption for key pre-specified outcomes for our planned analysis, namely receipt of any opioid 
between 90 and 180 days after surgery, total MME dispensed in the first 30 days after surgery, and receipt 
of any refill within 30 days. While we do observe statistically significant differences across study groups 
in trends over time in total MME received within 7 days after surgery, the magnitude of these differences 
is small in absolute terms and unlikely to be clinically significant. To assess this empirically, we will plan 
in the full study to conduct additional secondary analyses using estimators that account for differences in 
pre-exposure trends via matching or statistically controlling for such differences in the regression 
model.22 
 
In summary, we have presented the rationale and design for a planned study to assess the impact of the 
US FDA’s rescheduling of hydrocodone in 2014 from Category II to Category III of the controlled 
substances act on opioid prescribing practices after surgery. Additionally, prerequisite analyses presented 
here support the feasibility of the proposed approach and validate key analytic assumptions, while also 
highlighting important considerations for interpretation of subsequent analyses. Future work will 
implement this approach in the full study data set to measure the effect of the FDA hydrocodone 
rescheduling policy on postoperative opioid prescribing. 
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